SCHEMBL6442645

SCHEMBL6442645

N#Cc1c(NC2CCCCC2)nc(N)nc1-c1ccc2c(c1)OCO2

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 14/20 0.61
ADORA2A P29274 8/20 0.61
ADORA2B P29275 4/20 0.61
TBK1 Q9UHD2 1/20 0.46
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 3/20 0.46
HSD17B10 Q99714 3/20 0.46
USP2 O75604 1/20 0.46
TSHR P16473 1/20 0.46
HPGD P15428 2/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MEN1 O00255 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
ALOX15 P16050 1/20 0.43
ALOX12 P18054 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPK10 P53779 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6442381 0.80 ADORA1 (0.58) ADORA1ADORA2AADORA2B
SCHEMBL6441971 0.79 ADORA1 (0.61) ADORA1ADORA2AADORA2BTBK1KDM4E
SCHEMBL17544999 0.78 ULK1 (0.48) ADORA1ADORA2AADORA2BKDM4EHSD17B10
SCHEMBL6442437 0.78 ADORA1 (0.62) ADORA1ADORA2AADORA2BTBK1KDM4E
SCHEMBL6446302 0.76 ADORA1 (0.69) ADORA1ADORA2AADORA2BALDH1A1HSD17B10
SCHEMBL6441578 0.75 ADORA1 (0.67) ADORA1ADORA2AADORA2BKDM4EALDH1A1
SCHEMBL6447772 0.74 KDM4E (0.68) ADORA1ADORA2AADORA2BKDM4EALDH1A1
SCHEMBL6441820 0.74 ADORA1 (0.57) ADORA1ADORA2AADORA2BKDM4EALDH1A1
SCHEMBL6441330 0.73 ADORA1 (0.69) ADORA1ADORA2AADORA2BKDM4EALDH1A1
SCHEMBL6441880 0.73 ADORA1 (0.64) ADORA1ADORA2AADORA2BALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA1 3/4885ADORA2A 1/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.